|1.||Hoffmann, Jens: 7 articles (01/2011 - 07/2008)|
|2.||Klar, Ulrich: 6 articles (01/2011 - 07/2008)|
|3.||Giurescu, M: 4 articles (08/2012 - 03/2010)|
|4.||Hammer, Stefanie: 4 articles (01/2011 - 07/2008)|
|5.||Schmelter, Thomas: 3 articles (06/2013 - 10/2010)|
|6.||Sommer, Anette: 3 articles (01/2011 - 03/2010)|
|7.||Winsel, Sebastian: 3 articles (01/2011 - 07/2008)|
|8.||Eschenbrenner, Julia: 3 articles (01/2011 - 07/2008)|
|9.||Mittelstaedt, Kevin: 3 articles (01/2011 - 07/2008)|
|10.||Vahdat, Linda T: 3 articles (10/2010 - 04/2008)|
12/01/2012 - "Our study demonstrated clinically favorable safety, tolerability, and efficacy of sagopilone, which will help define the treatment of advanced tumors in more extensive clinical trials."
04/15/2010 - "Overall, micellar drug delivery systems for Sagopilone were identified offering the potential for an improved cancer therapy."
11/01/2011 - "Sagopilone treatment increased BMD In the mouse ovx model even though a non-optimized dose was used which is effective in tumor-bearing mice. "
12/01/2012 - "The purpose of this dose-escalation study was to investigate the safety, tolerability, and pharmacokinetics (PK) of sagopilone in refractory solid tumors. "
12/01/2009 - "In preclinical studies, sagopilone inhibited cell growth in a wide range of human cancer cell lines. "
|2.||Breast Neoplasms (Breast Cancer)
06/01/2009 - "Phase II clinical trials with sagopilone in patients with breast cancer are ongoing."
12/01/2011 - "Sagopilone was associated with modest CNS activity in patients with breast cancer; however median PFS was disappointing. "
01/01/2011 - "Here, we profiled sagopilone activity in breast cancer cell lines. "
01/01/2011 - "Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines."
12/01/2011 - "In this phase II study,we administered sagopilone to patients with breast cancer and brain metastases. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
11/01/2011 - "This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer. "
11/01/2011 - "Sagopilone is effective, with balanced tolerability, in patients with recurrent platinum-resistant ovarian cancer."
11/01/2011 - "Women with ovarian cancer recurring within 6 months of end of last platinum-containing treatment received sagopilone 16 mg/m(2) as a 3- or 0.5-h i.v. infusion every 21 days for up to 6 weeks. "
01/03/2012 - "This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC). "
12/01/2009 - "Initial reports revealed that sagopilone was clinically active in advanced ovarian cancer, advanced melanoma and metastatic chemotherapy-naïve castration-resistant prostate cancer. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/01/2010 - "A comparison with response rates for established drugs showed the strong efficacy of Sagopilone in non-small cell lung cancer. "
06/01/2013 - "This multicenter, randomized, open-label, phase II study examined the efficacy and safety of three regimens with two doses and two infusion durations of second-line sagopilone in pretreated patients with stage IIIB or IV non-small-cell lung cancer. "
06/01/2013 - "Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer."
01/01/2011 - "Sagopilone inhibited proliferation of non-small cell lung cancer cell lines at lower nanomolar concentration. "
01/01/2011 - "We analyzed the differential mechanism of action of sagopilone in non-small cell lung cancer cell lines in vitro. "
|5.||Peripheral Nervous System Diseases (PNS Diseases)
09/01/2011 - "Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administration."
01/01/2013 - "A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy."
01/01/2013 - "Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG). "
|3.||epothilone B (EPO906)
|4.||desoxyepothilone B (epothilone D)
|8.||Excipients (Suspending Agents)
|9.||ixabepilone (BMS 247550)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)